Helixberg | Intelligent Biotech Analysis

Expert insights on biotech catalyst trading, portfolios, and largest market movers.

Biotech trading is hard. We’re making it easy for you. We spent our entire professional careers in analyzing clinical data, valuing biotech firms, and making real, profitable trades in the market. No spin. No clickbait. Join now independent thinkers and become a better biotech trader and investor.

First-hand biotech insights

From seasoned healthcare professionals and hedge fund traders.

≥ 6 newsletters per month

A consistent set of tradable biotech catalyst and portfolio insights.

Trading decisions driven by clinical data

Receive guidance on what clinical data is needed for the stock to make a large move.

You will always get:

How does good clinical data for your biotech look like Fact-based price targets after clinical data read-out Fundamental competitor analysis

Your Biotech will be a 3x, if…

By Helixberg Jan, 2025
Donald Trump speaks during a Get Out the Vote Rally in March in Richmond, Virginia | Photo by Win McNamee/Getty Images
The peer group of drugs had the following endpoints in their trial releases.
These endpoints included primary measures such as changes in HbA1c levels, secondary outcomes like weight reduction, and safety profiles focusing on adverse event frequencies. Comparisons across the group showed variations in efficacy, with some drugs achieving significantly higher reductions in key markers. Additionally, certain candidates demonstrated superior tolerability, setting them apart in competitive positioning within the GLP-1 market.

Brief your next bio-tech trade!

Great! You’ve successfully signed up.
Welcome back! You've successfully signed in.
You've successfully subscribed to Helixberg | Intelligent Biotech Analysis.
Your link has expired.
Success! Check your email for magic link to sign-in.
Success! Your billing info has been updated.
Your billing was not updated.